By Katherine Hamilton
Atea Pharmaceuticals is reviewing strategic opportunities after cutting a quarter of its workforce.
The Boston biopharmaceutical company, which develops oral antiviral treatments, said Wednesday it has engaged an independent global investment bank to identify possible opportunities, including partnerships on its Phase 3 program for a treatment of patients with HCV.
It also reduced 25% of its employees during the first quarter in an effort to reduce costs. The reduction is expected to save $15 million through 2027, Atea said.
Write to Katherine Hamilton at katherine.hamilton@wsj.com
(END) Dow Jones Newswires
March 26, 2025 14:18 ET (18:18 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。